Gilead Sciences, an antiviral drugmaker, completed the acquisition of a 11.28% stake in Galapagos, a biotechnology company, specialized in the discovery and development of small molecule medicines, $1.1bn. “We are excited to enter into this unique agreement, which will generate both long-term strategic value and mutual, immediate benefits. We chose to partner with Galapagos because of its pioneering target and drug discovery platform, proven scientific capabilities and outstanding team,” Daniel O’Day, Gilead Chairman and Chief Executive Officer.